Skip to Content
Merck
All Photos(1)

Key Documents

P4670

Sigma-Aldrich

Propafenone hydrochloride

Synonym(s):

1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C21H27NO3 · HCl
CAS Number:
Molecular Weight:
377.90
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.77

form

powder

Quality Level

originator

Abbott

storage temp.

2-8°C

SMILES string

Cl[H].CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2

InChI

1S/C21H27NO3.ClH/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17;/h3-11,18,22-23H,2,12-16H2,1H3;1H

InChI key

XWIHRGFIPXWGEF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Propafenone hydrochloride is a calcium antagonist. It functions as a Na+ and K+ channel blocker. It might be used to treat patients with systemic hypertension. Propafenone hydrochloride is associated with bradycardia and bronchospasms. It is metabolized in the liver. Propafenone hydrochloride is used to treat ventricular arrhythmias.

Application

Propafenone hydrochloride has been used in the isolation of cardiomyocytes.

Biochem/physiol Actions

Blocks hKv1.5 and ATP-sensitive K+ channels; class 1C antiarrhythmic agent that is also an antagonist at β adrenergic receptors.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lori D Bash et al.
Cardiovascular drugs and therapy, 26(2), 167-179 (2012-03-16)
Rate and rhythm control are two well established treatment objectives for atrial fibrillation (AF) patients. While symptom reduction is a primary treatment goal, therapeutic practice related to cardioversion varies by region and patient, with several precautions associated with the use
Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study
Opolski G, et al.
Chest, 126(2), 476-486 (2004)
The multiple modes of action of propafenone
Dukes ID and Williams EMV
European Heart Journal, 5(2), 115-125 (1984)
Pharmacologic management of arrhythmias
Ganjehei L, et al.
Texas Heart Institute Journal, 38(4), 344-344 (2011)
Alexander Burashnikov et al.
The Journal of pharmacology and experimental therapeutics, 340(1), 161-168 (2011-10-19)
Ranolazine has been shown to produce atrial-selective depression of sodium channel-dependent parameters and suppress atrial fibrillation (AF) in a variety of experimental models. The present study contrasts the effects of ranolazine and those of a clinically used anti-AF class IC

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service